India Specifies Terms For Ceasing Supplies Of Essential Drugs
Executive Summary
India's apex pricing authority has specified the modalities for firms wanting to stop supplies of certain essential drugs in the country. Industry, though, claims that the regulator may have exceeded its remit and underscores how a lopsided pricing policy approach can lead to potential shortages.
You may also be interested in...
Stent Leaders Pull Out Of India Amidst Price Cap Storm; Opportunity For 'The Dragon'?
The storm in India over price caps on stents has not shown any signs of abating, with foreign firms seeking to pull back certain key brands and the pricing regulator resolute about maintaining market equilibrium. The slugfest also appears to have opened up the Indian market for Chinese firms, among others.
India's public sector pharma: flogging a dead horse?
Stop wasting public funds; privatize or perish; and the government has no business being in business, especially if the business is badly run. These appear to be common refrains of some experts on India's struggling public sector pharmaceutical firms – the bulk of which are sick.
Indian pricing body initiates action to check essential meds shortage
India's apex pricing authority has swung into action to tackle the ''scarcity'' of certain essential medicines including an antimalarial combination and rabies vaccines setting sharp compliance timelines for industry. Pharmaceutical firms, meanwhile, claim the current situation is a result of the government's own lopsided pricing policy.